Editas Medicine, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
EDIT Nasdaq 2830 www.editasmedicine.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Editas Medicine, Inc.

Editas Surpasses Therapeutic Gene Editing Threshold in New Preclinical Data - Jul 3rd, 2025 7:09 am
Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now? - Jun 28th, 2025 3:04 am
2 Beaten-Down Stocks to Avoid - Jun 27th, 2025 6:15 am
Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - Jun 17th, 2025 8:07 am
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June - Jun 12th, 2025 12:01 am
Why Is Editas (EDIT) Up 40% Since Last Earnings Report? - Jun 11th, 2025 9:30 am
1 Stock Down 97% That Could Double, According to Wall Street - May 25th, 2025 4:00 am
A new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territory - May 15th, 2025 1:11 am
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June - May 14th, 2025 7:31 am
Editas Medicine First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - May 14th, 2025 5:32 am
Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting - May 14th, 2025 5:01 am
Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year? - May 13th, 2025 7:40 am
Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y - May 13th, 2025 6:42 am
Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting - May 13th, 2025 5:01 am
Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates - May 12th, 2025 3:45 pm
Editas: Q1 Earnings Snapshot - May 12th, 2025 2:48 pm
Editas Medicine Announces First Quarter 2025 Results and Business Updates - May 12th, 2025 2:30 pm
Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board - May 12th, 2025 2:01 pm
Editas (EDIT) Upgraded to Buy: What Does It Mean for the Stock? - May 12th, 2025 10:00 am
Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May - May 5th, 2025 2:01 pm